ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1330

Prednisone Use Associated With Worse Outcomes In Rheumatoid Arthritis Pregnancies

Prateek Chaudhary1 and M. E. B. Clowse2, 1Division of Rheumatology, Duke University Medical Center, Durham, NC, 2Rheumatology, Duke University Medical Center, Durham, NC

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Prior reports suggest that disease activity in rheumatoid arthritis (RA) improves in the setting of pregnancy.  However, prior studies report half of patients having moderate-severe disease activity throughout pregnancy; these are levels of activity unacceptable in our current RA treatment paradigm.  The use of TNF-inhibitors remains controversial in pregnancy with many clinicians more comfortable with prednisone. The purpose of this study was to prospectively evaluate RA disease activity and medication use as predictors of pregnancy outcomes.

Methods:

RA pregnancies were followed prospectively in a single clinic. An assessment of each patient was performed at all pregnancy and postpartum visits, and included demographic data and measures of disease activity, such as the physician global assessment (PGA) and 28 joint DAS-CRP. A DAS-CRP <2.6 was considered remission.  Medication use was determined in collaboration between the physician and patient. Outcome measures included the presence of a miscarriage, preterm birth or preeclampsia. Non-parametric testing was used for the analysis.

Results:

The 31 pregnancies in this cohort had a mean age of delivery of 32.5 years; 23 (74.2%) of mothers were Caucasian. Nine (29%) were exposed to TNF-inhibitors, while 15 (48.4%) were exposed to prednisone. 2 pregnancies (6.5%) ended in early miscarriages, neither with prednisone or TNF-inhibitor exposure and both with low RA activity.  Of the 29 live births, preterm delivery occurred in 5 (17.2%) and preeclampsia in 3 (10.9%). Remission was achieved in 54% of women in the 1st trimester, 77% in the 2nd trimester, 67% in the 3rd trimester, and 61% postpartum. There was a strong correlation between DAS-CRP and PGA (R=0.86). Higher disease activity in the 1st trimester was associated with an increased risk of preterm birth (DAS-CRP = 5.58 preterm vs. 2.20 term, p=0.028; PGA= 30.0 preterm vs. 75.2 term, p=0.019). All pregnancies fell into one of three 1st trimester medication groups (table). Hydroxycholoroquine and sulfasalazine were evenly distributed in each group and did not appear to impact pregnancy outcomes.  The patients with neither TNF-inhibitor nor prednisone exposure had a mean 1st trimester DAS-CRP of 1.63, while patients exposed to prednisone or TNF-inhibitor had a mean DAS-CRP of 3.92 or 3.19, respectively. Over half of patients (54.2%) exposed to prednisone had preterm birth and/or preeclampsia compared to 14.3% of those with TNF-inhibitor exposure.  

Conclusion:

In the 1st trimester, high RA activity and prednisone use are both associated with an increased risk of preterm birth and/or preeclampsia. While both the prednisone and TNF-inhibitor groups had similar disease activity in the 1st trimester, prednisone use was significantly associated with a higher risk of adverse outcome. This study suggests that TNF-inhibitors may be preferable to prednisone in RA pregnancies.

Table: Medication group and pregnancy outcome

Medication

 

Mean 1st Trimester DAS-CRP

Preterm Birth

Preeclampsia

Either preterm birth or preeclampsia

No Prednisone or TNF-Inhibitor

1.63

0%

0%

0%

Prednisone

3.92

36.4%

27.3%

54.5%

TNF-Inhibitor

3.19

14.3%

0%

14.3%

p-value

0.150

0.086

0.099

0.0078*

 


Disclosure:

P. Chaudhary,
None;

M. E. B. Clowse,

UCB,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prednisone-use-associated-with-worse-outcomes-in-rheumatoid-arthritis-pregnancies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology